By Shelley Campeau, PhD, D(ABMM)
LEARNING OBJECTIVES
Upon completion of this article, the reader will be able to:
- Discuss the current outbreak of drug-resistant Pseudomonas aeruginosa.
- Describe the background and epidemiology of carbapenem-resistant P. aeruginosa (CP-CRPA).
- Differentiate between different testing methods for CP-CRPA.
- List the entities and guidelines involved to combat future carbapenem-resistant P. aeruginosa (CP-CRPA) outbreaks.
About the Author
Shelley Campeau, PhD, D(ABMM) is a Diplomate of the American Board of Medical Microbiology and currently a Senior Consultant with Scientific and Medical Affairs Consulting, LLC. Prior to consulting, she worked in both clinical and public health microbiology for over 10 years, and then in industry at an in vitro diagnostics company for 4 years. She has been a volunteer with CLSI for almost 10 years, helping to bring updated breakpoints and new test methods to clinical laboratories for improved patient care.
Photo credit: 12943472 © Monika Wisniewska | Dreamstime.com